Hematological Awareness
The incidence of cancer is increasing rapidly; therefore it is important to step up cancer literacy and knowledge amongst the population.
Early
Screening looks for early signs of cancer or pre-cancerous conditions before any symptoms appear.
Hematological Cure
We are committed in extending holistic knowledge, treatment and rehabilitation through its “Rise Against Cancer” movement.
KPV Multispeciality Clinics
Plans to build educated human resources, awareness and preventive initiatives, and a single technological platform to deliver high-quality care are supplementing infrastructure development.
Dr. Srikanth
Haematology
Dr. Srikanth’s passion for medicine began at an early age when he witnessed the transformative impact of healthcare professionals on patients’ lives. This sparked his determination to pursue a career in medicine, with a specific focus on hematological disorders. After completing his undergraduate studies with honors, Dr. Srikanth joined a prestigious medical school, where his dedication to learning and remarkable academic performance garnered praise from both peers and mentors.
Beyond his impressive medical accomplishments, Dr. Srikanth’s patients speak of his unparalleled compassion and unwavering commitment to their well-being. As a hematologist, he understands the anxiety and fear that often accompany blood disorders. With a warm and empathetic demeanor, he takes the time to listen to his patients’ concerns and collaborates with them to develop personalized treatment plans. Many of his patients credit him with not only saving their lives but also helping them navigate the emotional challenges that come with chronic illnesses.
ACADEMIC QUALIFICATIONS
| Year | Qualified at | Place |
|---|---|---|
| 1996 | Primary Medical Degree M.B.B.S | Kilpauk Medical College, Madras, India |
| 2000 | Postgraduate Degree M.R.C.P | Royal College of Physicians,United Kingdom |
| 2006 | Higher specialisation F.R.C.Path (Haematology) | Royal College of Pathologists United Kingdom |
| 2007 | Awards/Grants General Clinical Research Fund | Royal Marsden Hospital UK |
| 2008 | Certification CCT | Haematology ,PMETB UK |
| 2011 | Research Degree MD(Res) | Royal Marsden Hospital UK |
INTERNATIONAL EXPERIENCE
| Year | POSSESSION | Place |
|---|---|---|
| 2006 - 2009 | MD | Royal Marsden Hospital/Indtitute of cancer Research Uk |
| 2009 - 2011 | SENIOR CONSULTANT | Ealing Hospital NHS Trust and Hammersmith Hospitals London |
| 2011 - 2012 | SENIOR CONSULTANT | Medway Maritime Hospital (Attached to Kings College London) |
| 2012 - 2016 | SENIOR CONSULTANT | Ashford & St. Peter's Hospitals (Attached to University college London |
INTERNATIONAL PUBLICATION
Srikanth M, Jenner M, Wu P, Kaczmarek P, Dines S, Saso RM, Ethell M, M Potter M, Treleaven JG, Davies FE, Morgan GJ Survival and Outcome of Blastoid Variant Myeloma Following Treatment with DT-PACE. Haematologica .2007; 92:712.
Morgan GJ, Schey SA, Wu P, Srikanth M, Phekoo KJ, Jenner M, Davies FE. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol. 2007;137:268-9.
Davies FE, Wu P, Jenner M, Srikanth M, Saso R, Morgan GJ. The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica 2007;92:1149-50.
Davies FE, Srikanth M, Wu P, Jenner M, McCormack R, Cordero F, Trudel G, Morgan GJ. The Combination of Velcade, Idarubicin and Melphalan (VIM) Demonstrates Significant clinical activity in relapsed/refractory myeloma patients. Blood 2007;110:2727.
Srikanth M, Davies F E, Morgan GJ. Update on novel drug combinations in Multiple Myeloma. Expert opinion on Investigational Drugs. 2008;17:1-12.
Moore HE, Davenport EL, Smith EM, Muralikrishnan S, Dunlop AS, Walker BA, Krige D, Drummond AH, Hooftman L, Morgan GJ, Davies FE. Aminopeptidase Inhibition as a Targeted Treatment Strategy in Myeloma. Molecular Cancer Therapy,2009:762-770.
Aronson L, Davenport EL, Giuntoli SG, Srikanth M, Smith E, Morgan GJ, Davies FE.
Autophagy is a key myeloma survival pathway that can be manipulated therapeutically to enhance apoptosis. Blood 2010: 4083
SCIENTIFIC PROJECTS
ROYAL MARSDEN HOSPITAL / INSTITUTE OF CANCER RESEARCH UK 2006-2008
Prof Gareth J Morgan and Dr F E Davies: Working in the above International institutions with the International experts I have gained immense experience in the Drug development of Myeloma and translational research leading to Phase1/2 clinical trials.
Projects during MD (Res)
Prinicipal Scientific: Effect of novel agents in myeloma
PI3 Kinase in Multiple Myeloma (PI-103)
Other Scientific : KW-2478 in Myeloma and CLL (Hsp-90 inhibitor)
Other Scientific : CHR-2797 in Myeloma (aminopeptidase inhibitor)
Book an Appointment Now!
Please contact our courteous reception staff if you have any general or medical questions. Any urgent calls will be received or returned by our doctors.
- Experienced Specialist Doctors
- Excellent Nursing Care
-
Excellent Patient Care
-
Friendly Ambience
-
Equal treatment
CONSULTATION HOURS
Monday to Friday : 4.30 pm to 10 pm
Saturday: 2 pm to 5 pm
Address
New number 128 old number 73
Varadhammal Garden, 3rd Street,
Secretariat Colony, Kilpauk
CHENNAI, TAMIL NADU 600010
Phone Number
+91 72001 65148
+91 93447 46686
rajsrikkanth@hotmail .com
info@drsrikanth.org.in